Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters
Background For the purpose of understanding the Food and Drug Administration’s (FDA’s) concerns regarding online promotion of prescription drugs advertised directly to consumers, this study examines notices of violations (NOVs) and warning letters issued by the FDA to pharmaceutical manufacturers....
Main Author: | Hyosun Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Kerman University of Medical Sciences
2015-12-01
|
Series: | International Journal of Health Policy and Management |
Subjects: | |
Online Access: | http://www.ijhpm.com/pdf_3083_c5885a53cd19640e9d9aa3171a12269f.html |
Similar Items
-
Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries
by: Hyosun Kim
Published: (2016-10-01) -
The Tip of the Iceberg of Misleading Online Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Barbara Mintzes
Published: (2016-05-01) -
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better?; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Evan Doran
Published: (2016-05-01) -
Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Brent L. Rollins
Published: (2016-04-01) -
The Conundrum of Online Prescription Drug Promotion Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Isaac Wanasika
Published: (2016-06-01)